A Clinical Stage Fc-engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies
Steven J. O’Day, M.D., Executive Director of the Saint John’s Cancer Institute and Cancer Clinic, and Director of Providence Los Angeles Regional Research, presented Agenus NextGen CTLA-4 Antibody (AGEN1181) Data at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program held on May 29-31, 2020.
AGEN1181 is a multifunctional Fc-engineered next generation anti-CTLA-4 antibody which has been designed to improve upon the safety and efficacy shown with first-generation CTLA-4 antibodies.
